Advertisement
UK markets close in 39 minutes

  • FTSE 100

    8,049.38
    +4.57 (+0.06%)
     

  • FTSE 250

    19,738.22
    -61.50 (-0.31%)
     

  • AIM

    754.96
    +0.09 (+0.01%)
     

  • GBP/EUR

    1.1630
    +0.0002 (+0.02%)
     

  • GBP/USD

    1.2434
    -0.0019 (-0.15%)
     

  • Bitcoin GBP

    52,350.27
    -1,309.80 (-2.44%)
     

  • CMC Crypto 200

    1,408.68
    -15.42 (-1.08%)
     

  • S&P 500

    5,069.28
    -1.27 (-0.03%)
     

  • DOW

    38,428.79
    -74.90 (-0.19%)
     

  • CRUDE OIL

    83.55
    +0.19 (+0.23%)
     

  • GOLD FUTURES

    2,339.70
    -2.40 (-0.10%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,104.85
    -32.80 (-0.18%)
     

  • CAC 40

    8,094.61
    -11.17 (-0.14%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Sanofi and AstraZeneca to exchange 210,000 chemical compounds

Reuters - UK Focus

(Corrects number in headline)

Nov 20 (Reuters) - Sanofi (NasdaqGM: GCVRZ - news) and AstraZeneca (Swiss: AZN.SW - news) said on Friday that they will exchange 210,000 chemical compounds in a deal aimed at widening the diversity of the chemicals they can use to develop new drugs.

The compounds exchanged have been selected based on differences from those already existing in their own libraries, the companies said in a statement.

Each company will be able to research the compounds for use in any disease without restrictions.

There are no payments associated with the agreement, either upfront or if a compound becomes part of a successful clinical candidate.

(Reporting by Alan Charlish, editing by Dominique Vidalon)